Paradigm’s (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regenerati...See more
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
11-50 Employees
Year Founded:
2014 (12 years)
Address:
500 COLLINS; L2 517 FLINDERS LANE; MELBOURNE, VICTORIA 3000, AU
HIGH
spending power
